Clinical trial registry record

Colorectal Cancer (CRC) Cetuximab Elderly Frail

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 10, 2016.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01522612
Last registry update
June 10, 2016
Status
Terminated
Phase
Phase 2
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Enrollment
5
Countries
Belgium, Cyprus, Spain
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
5
Population
ALL · 70 Years
Duration
2013-04-01 to 2015-01-01
Intervention
Cetuximab; 5-fluorouracil; leucovorin
Comparator
5-fluorouracil/leucovorin alone
Outcomes measured
Progression free survival — 19 months from first patient in; Overall Survival — 19 months from first patient in; Response Rate — 19 months from first patient in; Change in Instrumental Activities of Daily Living (IADL) score — 19 months from first patient in; Change in G8 geriatric assessment screening tool — 19 months from first patient in; Change in social situation — 19 months from first patient in; Score of Quality of Life (EORTC-QLQ C30 and QLQ-ELD14) — 14 days before randomization; 6 weeks, 14 weeks, 22 weeks and…; Occurrence of adverse events — 19 months from first patient in; Health Economy assessments — 19 months from first patient in; Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by G8 instrument — 14 days b…; Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by Instrumental Activities o…; Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation question…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON